Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy

Launched by WEN-HONG ZHANG · Jul 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a specific marker in the blood, called HBV pgRNA, can help predict long-term health outcomes for patients with chronic hepatitis B (HBV) who are receiving antiviral treatment. The goal is to better understand how this marker might indicate whether a patient will develop complications like liver cancer (HCC) in the future.

To participate in this study, individuals must be between 18 and 80 years old and have chronic hepatitis B, which is confirmed by a positive hepatitis B surface antigen test. Participants will undergo regular check-ups and blood tests during their treatment. It's important to note that this trial is not yet recruiting participants, and those with other types of cancer besides liver cancer will not be included. Overall, the findings from this research could help doctors improve treatment strategies for hepatitis B patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • CHB defined as positive hepatitis B surface antigen at least 6 months, or HBV-related histological changes within 1 year if HBsAg positive less than 6 months;
• • Age between 18-80 years, gender is not limited；
• • Patients with chronic hepatitis B who have been determined by clinicians to start, or have already taken the first-line treatment {including pegylated interferon \[IFN\] monotherapy, a potent nucleos(t)ide analogue \[NA\] monotherapy, two different potent NAs combination therapy, or NA plus IFN combination therapy;
• • Patient who reads and signs informed consent.
• Exclusion Criteria:
• • Patients with malignancies other than hepatocellular carcinoma.